Remote monitoring can reduce hassle for expecting mothers in low-risk pregnancies

A woman going through pregnancy shouldn’t actively avoid going to the doctor—but Allison Matthews, considered at low risk for certain complications like preeclampsia during her first pregnancy, didn’t see much benefit in shuffling to and from physicians’ offices.

“I was taking time off work and it wasn’t doing a lot for me,” said Matthews. “I kind of felt like I was almost doing it more for the clinic’s benefit than for myself.”

The clinical services designer at Mayo Clinic, she enrolled in OB Nest program for her second pregnancy, which is designed for low-risk expectant mothers to self-monitor specific vital signs. Matthews would also cut her clinic visits from 12 or 14 to just eight.

The modified process matched Matthews’ approach to pregnancy, allowing the at-home monitoring to become a family event, rather than a personal hassle for her.

“It was something we explored together rather than having it done for us,” said Matthews, 35. Their daughter, Lottie, was born about a month ago.

Read the full story from Kaiser Health News at the link below:

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.